Skip to main content

Search
Pulmonary and Sleep Medicine

Research Funding

|

Research Funding

Grant TitleGrantorAmountAward Date
Nicole Hamblett, PhDRates of Hemoptysis Among Individuals with Cystic Fibrosis Enrolled in Clinical TrialsPharmaxis Ltd.Feb. 1, 2014
Nicole Hamblett, PhDLong Term Outcomes After Eradication of Pseudomonas Aeruginosa Among Children Enrolled in EPIC ClinicalNovartis Pharmaceuticals Corp.Dec. 15, 2013
Nicole Hamblett, PhDOptimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZENIH/NHLBISept. 15, 2013
Bonnie W. Ramsey, MDOptimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial Clinical Coordinating CenterNIH/NHLBISept. 15, 2013
Benjamin S. Wilfond, MDITHS Supplement - Attitudes about the Ethics of Standard of Care ResearchNIH/NCATSSept. 13, 2013
Nicole Hamblett, PhDG551D Observational Study Expanded to Include Additional Genotypes and Extended for Long Term FollowupCystic Fibrosis Foundation TherapeuticsSept. 1, 2013
Benjamin S. Wilfond, MDClinical Implementation of Carrier Testing Using NGSNIH/NHGRIJune 15, 2013
Bonnie W. Ramsey, MDInfant Study of Inhaled Saline in Cystic Fibrosis (ISIS)Cystic Fibrosis Foundation TherapeuticsOct. 1, 2012
Bonnie W. Ramsey, MDBaby Observational and Nutritional Study of Cystic Fibrosis (BONUS)NIH/NIDDKAug. 3, 2012
Nicole Hamblett, PhDA Multicenter Study of the Effects of AquADEKs-2 on Markers of Inflammation and Oxidative Stress in CFCystic Fibrosis Foundation TherapeuticsAug. 1, 2012
Sonya Heltshe, PhDCell Phone Spirometry Pilot in CF PatientsCoulter FoundationJuly 1, 2012
Bonnie W. Ramsey, MDInstitute for Translational Health SciencesNIHJune 1, 2012
Benjamin S. Wilfond, MDInstitute of Translational Health SciencesNIH/NCATSJune 1, 2012
Bonnie W. Ramsey, MDMolecular Biology of Cystic FibrosisCystic Fibrosis FoundationOct. 1, 2011
Bonnie W. Ramsey, MDInfant Study of Inhaled Saline in Cystic Fibrosis (ISIS)NIH/NHLBIAug. 1, 2011
Bonnie W. Ramsey, MDEarly Intervention in CF Exacerbation (eICE Study)Cystic Fibrosis Foundation TherapeuticsAug. 1, 2011
Bonnie W. Ramsey, MDInfant Nutrition Study of Newborns with Cystic FibrosisCystic Fibrosis Foundation TherapeuticsFeb. 1, 2011
Bonnie W. Ramsey, MDNewly Acquired MRSA Eradication ProtocolCystic Fibrosis Foundation TherapeuticsSept. 1, 2010
Bonnie W. Ramsey, MDTranslational Research Center to Expedite Novel Therapies in Cystic FibrosisNIH/NIDDKJuly 6, 2010
Sonya Heltshe, PhDTranslational Research Center to Expedite Novel Therapies in Cystic Fibrosis (P30)NIH/NIDDKJuly 6, 2010
Bonnie W. Ramsey, MDEarly Intervention in Pulmonary Exacerbation in CFNIH/NHLBIJuly 1, 2010
Benjamin S. Wilfond, MDCenter for Genomics and Healthcare EquityNIH/NHGRIMay 14, 2010
Nicole Hamblett, PhDPseudomonas Aeruginosa Adaptation During Early CF Airway Infection and TreatmentNIHSept. 11, 2009
Bonnie W. Ramsey, MDEPIC Observational StudyCystic Fibrosis Foundation TherapeuticsApril 1, 2009
Nicole Hamblett, PhDInstitute of Translational Health SciencesNIH/NCATSSept. 17, 2007
Gregory J. Redding, MDPEDIATRIC PULMONARY TRAINING GRANT, SEATTLE, WASHINGTONU.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, MATERNAL AND CHILD HEALTH BUREAU, HRSAJuly 1, 2005
Bonnie W. Ramsey, MDTherapeutics Development Network Coordinating CenterCystic Fibrosis Foundation TherapeuticsApril 1, 2003
Sonya Heltshe, PhDTherapeutics Development Network Coordinating CenterCystic Fibrosis Foundation TherapeuticsApril 1, 2003
Maida Lynn Chen, MDA Multicenter Retrospective with Prospective follow-Up Study of Early Onset Childhood Narcolepsy: Recent cases and Post infection (EON)Jazz
Maida Lynn Chen, MDMidface and Positive Airway Pressure (MAP)
Maida Lynn Chen, MDSleep, Temperament, and Arousal Regulation in Infants with Prenatal ExposureCCTR
Maida Lynn Chen, MDCPAP Adherence Factors
Jason Scott Debley, MD, MPHAirway Epithelial Cell Cytokine Profiles of Children with and without AsthmaNIH/NIAID, NIH/NHLBI, Benaroya Research Institute, Amgen, Firlands Foundation
Jason Scott Debley, MD, MPHNoninvasive Measures of Airway Inflammation and Airflow Obstruction in Wheezy Infants and Toddlers
Ron Gibson, MD, PhDCystic Fibrosis Bronchoalveolar Lavage Fluid Specimen BankCystic Fibrosis Foundation
Ron Gibson, MD, PhDRole of Islet Amyloid and IL-1 Signaling in -cell Loss in Cystic Fibrosis Related DiabetesNIH
Ron Gibson, MD, PhDAn Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis (VX08-770-105)Vertex
Ron Gibson, MD, PhD A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation (VX11-770-110)Vertex
Ron Gibson, MD, PhDA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-103Vertex
Ron Gibson, MD, PhDA Phase 3, Blinded, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-105)Vertex
Ron Gibson, MD, PhDComparison study of regulatory T cell phenotypes and function in blood samples from individuals with CF and healthy non-CF controlsCystic Fibrosis Foundation
Ron Gibson, MD, PhDThe EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002)Cystic Fibrosis Foundation $, $
Ron Gibson, MD, PhDCF EPIC Participation in the NHLBI Lung Cohorts Sequencing ProjectNIH
Ron Gibson, MD, PhDPrediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)NIH
Ron Gibson, MD, PhDDirector, Clinical Core, Cystic Fibrosis Research Development ProgramCystic Fibrosis Foundation
Ron Gibson, MD, PhDCo-director, Clinical Core, P30 Translational Research Center to Expedite Novel Therapies in Cystic FibrosisNIH
Ron Gibson, MD, PhDCystic Fibrosis Foundation National Patient RegistryCystic Fibrosis Foundation
Ron Gibson, MD, PhDEarly Intervention in CF ExacerbationNIH
Ron Gibson, MD, PhDI Change Adherence and Raise ExpectationsNovartis
Ron Gibson, MD, PhDA Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis PatientsMPex
Ron Gibson, MD, PhDEarly MRSA Therapy in CF- culture based vs observant therapy (treat or observe) (STAR-too)Cystic Fibrosis Foundation
Luke Hoffman, MD, PhDBaby Observational and Nutrition StudyCystic Fibrosis Foundation
Luke Hoffman, MD, PhDStaphylococcus aureus small-colony variants: Optimal testing and treatmentCCTR
Luke Hoffman, MD, PhDHigh-resolution fluorescent microscopic characterization of CF polymicrobial lung infectionsCystic Fibrosis Foundation
Luke Hoffman, MD, PhDThe relationship of fecal microbiomes and nutritional status in CFCystic Fibrosis Foundation
Luke Hoffman, MD, PhDDescribing the CF Gut Microbiome in Infancy and Early ChildhoodNIH
Luke Hoffman, MD, PhDCommunity-level Physiologic Profiling of Whole Cystic Fibrosis SputumCystic Fibrosis Foundation
Luke Hoffman, MD, PhDThe roles of Staphylococcus aureus and Pseudomonas aeruginosa adapted forms in cystic fibrosis (CF) lung diseaseCystic Fibrosis Foundation
Luke Hoffman, MD, PhDChanges in CF Respiratory Microbiota During Treatment With Kalydeco in People with the G551D MutationNIH
Luke Hoffman, MD, PhDPseudomonas aeruginosa adaptation During Early Cystic Fibrosis Airway Infection and TreatmentCystic Fibrosis Foundation
Thida Ong, MDProspective Cohort Study of Severe Bronchiolitis and Risk of Recurrent WheezingNIH
Margaret Rosenfeld, MD, MPHValidation of a novel cell-phone spirometer in pediatric patients with respiratory diseasesITHS and Coulter Foundation
Margaret Rosenfeld, MD, MPHNovel Home Cough Monitor in Young Children with Cystic Fibrosis: A Pilot and Feasibility StudyCCTR
Margaret Rosenfeld, MD, MPHThe EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002)Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPHParent Report of Respiratory and Gastrointestinal Signs in Infants and Young Children with Cystic Fibrosis: A Feasibility studyCCTR
Margaret Rosenfeld, MD, MPHInfant Study of Inhaled SalineNIH and Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPHA Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis and a CFTR Gating Mutation, Age 2to 5Years (VX11-770-108)Vertex
Margaret Rosenfeld, MD, MPHA Phase 3, 2 Arm, Roll-Over Study to Evaluate the Long Term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation (VX11-770-109)Vertex
Margaret Rosenfeld, MD, MPHA Phase 1, Open-Label Study to evaluate the Pharmacokinetics and Safety of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-011)Vertex
Margaret Rosenfeld, MD, MPHDevelopment of an Observer Reported Outcome of Respiratory Signs for Young Children with Cystic FibrosisCCTR
Margaret Rosenfeld, MD, MPHStudy of Inhaled Saline in Preschool Children with CF (SHIP): Planning GrantCystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPHLongitudinal Study of Primary Ciliary Dyskinesia: Participants 5 -18 Years of Age (Protocol 5901)NIH
Margaret Rosenfeld, MD, MPHEarly Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age (RDN #5903)NIH
Margaret Rosenfeld, MD, MPHTesting a Multifactorial Caries Model for Pediatric Patients with Cystic FibrosisSunstar and Cystic Fibrosis Foundation
Yemiserach Kifle, MDForamen Magnum Stenosis in Achondroplasia: The Value of Screening by Polysomnography
Amanda Striegl, MD, MSSpinal Muscular Atrophy Research Database: A Multicenter Multidisciplinary AssessmentFamilies of Spinal Muscular Atrophy
Academic Annual Report